Goldman Sachs
HRTX icon

Goldman Sachs’s Heron Therapeutics HRTX Stock Holding History

Goldman Sachs’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-155,000
Closed -$2.88M – 5255
2019
Q2 		$2.88M Buy
+155,000
New +$3.1M ﹤0.01% 3269
2018
Q1 		– Sell
-1,700
Closed -$31K – 6108
2017
Q4 		$31K Buy
1,700
+1,100
+183% +$17.9K ﹤0.01% 6038
2017
Q3 		$10K Buy
+600
New +$9.41K ﹤0.01% 6531
2017
Q2 		– Sell
-1,400
Closed -$21K – 6842
2017
Q1 		$21K Buy
+1,400
New +$19.4K ﹤0.01% 6500
2016
Q4 		– Sell
-100
Closed -$2K – 6970
2016
Q3 		$2K Sell
100
-6,500
-98% -$121K ﹤0.01% 6965
2016
Q2 		$119K Sell
6,600
-43,400
-87% -$847K ﹤0.01% 6035
2016
Q1 		$950K Buy
50,000
+47,500
+1,900% +$937K ﹤0.01% 4114
2015
Q4 		$67K Sell
2,500
-499,300
-100% -$13.4M ﹤0.01% 6401
2015
Q3 		$12.2M Buy
+501,800
New +$16.7M ﹤0.01% 2097

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Goldman Sachs's HRTX Position: Q2 2026 in Review

Goldman Sachs increased its Heron Therapeutics (HRTX) stake by 26% in Q2 2026, buying an estimated $219K and bringing the position to 1,329,754 shares worth $568K. The position accounts for ﹤0.01% of the portfolio, ranked #5624.

Goldman Sachs first reported a position in HRTX in Q1 2014 and has held it in 47 quarters since. The position peaked at $36.1M in Q4 2019. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Goldman Sachs held 1,329,754 shares of Heron Therapeutics worth $568K as of Q2 2026.
  • Goldman Sachs bought 272,810 Heron Therapeutics shares in Q2 2026, an estimated $219K.
  • Heron Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5624 holding.
  • Goldman Sachs first reported a position in Heron Therapeutics in Q1 2014 and has held it in 47 quarters since.
  • Goldman Sachs's Heron Therapeutics position peaked at $36.1M in Q4 2019.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.